KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, SwitzerlandRead More
For over 20 years, Selexis has built collaborations, partnerships, and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Our innovative and proprietary cell line development technologies significantly reduce the time, effort, and costs that are associated with developing high-performance mammalian cell lines used for innovative therapies. (e.g., mAbs, growth factors and enzymes).
The increaing complexity of these novel therapeutic proteins place immense pressure on the Chinese Hamster Ovary (CHO) cell lines which is the standard workhorse typically used to express such molecules. This led Selexis to utilize it's multi-disciplinary expertise to engineer and create the CHO-Mplus libraries that address expression bottlenecks related to transcription, translation, DNA repair, secretion, protein folding, glycosylation etc. Utilizing modular workflows the optimal CHO host for expression and production of the desired protein candidate can be identified. Leveraging a robust panel of analytical methods early in the cell line development process allows for early characterization of the expressed protein to ensure that only cell clones producing proteins with the desired attributes are advanced through the development process. To mitigate manufacturing risks, Selexis has also developed cell line characterization modules based on next generation sequencing (NGS) methods. These allow for comprehensive genetic characterization, clonality assessment and authentication of the CHO manufacturing cell lines.